Bellevue reports 1.2M shares (1.5%) of Celldex

Rhea-AI Filing Summary

Celldex Therapeutics, Inc. ownership disclosure: Bellevue Group and its wholly owned subsidiary Bellevue Asset Management AG report beneficial ownership of 1,200,000 shares of Common Stock, representing 1.5% of Common Stock deemed outstanding (based on 78,492,072 shares). This Amendment No. 1 is described as an exit filing because the reporting persons now own less than five percent.

Insights

Institutional Ownership Specialist

Large shareholder reports a sub-5% position and files an amendment.

Bellevue Group and Bellevue Asset Management AG jointly report beneficial ownership of 1,200,000 shares (1.5%), with shared voting and dispositive power reported. The filing characterizes this Amendment No. 1 as an exit filing because holdings fell below 5%.

Cash‑flow treatment or sale mechanics are not stated; subsequent filings would show any disposition details.

Key Figures

Beneficial ownership: 1,200,000 shares Percent of class: 1.5% Shares deemed outstanding: 78,492,072 shares +2 more

5 metrics

Beneficial ownership 1,200,000 shares Amount beneficially owned (reported in Item 4)

Percent of class 1.5% Percent of Common Stock based on deemed outstanding

Shares deemed outstanding 78,492,072 shares Basis for percentage calculation stated in the filing

Shared voting power 1,200,000 shares Shared power to vote reported in Item 4(c)(ii)

Signature date 05/11/2026 Signed by Bellevue officers on Amendment No. 1

Key Terms

Amendment No. 1, Schedule 13G/A, beneficially owned, shared dispositive power, +1 more

5 terms

Amendment No. 1 regulatory

"This Amendment No. 1 constitutes an exit filing for the Reporting Person"

Schedule 13G/A regulatory

"This statement is filed jointly by Bellevue and BAM AG"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficially owned financial

"Amount beneficially owned: 1,200,000"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared dispositive power financial

"Shared Dispositive Power 1,200,000.00"

exit filing regulatory

"This Amendment No. 1 constitutes an exit filing for the Reporting Person"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Bellevue Group report in CLDX?

Bellevue Group and Bellevue Asset Management AG report beneficial ownership of 1,200,000 shares, representing 1.5% of Common Stock based on 78,492,072 shares deemed outstanding. The filing is an Amendment No. 1 described as an exit filing.

Does the filing show who controls the shares for CLDX?

The filing reports shared voting power and shared dispositive power of 1,200,000 shares. Sole voting and dispositive power are reported as 0, indicating joint control through the named entities.

Is Bellevue still a 5% owner of CLDX after this amendment?

No. The Amendment No. 1 states the reporting persons own less than 5% and explicitly calls this document an exit filing. The disclosed percentage is 1.5% based on the stated outstanding share count.

Who filed the Schedule 13G/A for CLDX and when?

The Schedule 13G/A was filed jointly by Bellevue Group AG and its wholly owned subsidiary Bellevue Asset Management AG. Signatures shown are dated 05/11/2026 on the Amendment No. 1.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 02:37 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Celldex Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

15117B202

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 15117B202

1

Names of Reporting Persons

Bellevue Group AG

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

SWITZERLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,200,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,200,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,200,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.5 %

12

Type of Reporting Person (See Instructions)

HC, CO

Comment for Type of Reporting Person: The percentage set forth in Row 11 is calculated based on 78,492,072 shares of Common Stock deemed outstanding. This Amendment No. 1 constitutes an exit filing for the Reporting Person as the Reporting Person owns less than five percent (5%) of the common shares of the Issuer.

SCHEDULE 13G

CUSIP Number(s): 15117B202

1

Names of Reporting Persons

Bellevue Asset Management AG

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

SWITZERLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,200,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,200,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,200,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.5 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: The percentage set forth in Row 11 is calculated based on 78,492,072 shares of Common Stock deemed outstanding. This Amendment No. 1 constitutes an exit filing for the Reporting Person as the Reporting Person owns less than five percent (5%) of the common shares of the Issuer.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Celldex Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: Perryville III Building, 53 Frontage Road, Suite 220, Hampton, NJ 08827
Item 2.
(a)	Name of person filing: Bellevue Group AG ("Bellevue") on behalf of its wholly-owned subsidiary, Bellevue Asset Management AG ("BAM AG")
(b)	Address or principal business office or, if none, residence: Bellevue: Theaterstrasse 12, Zurich, Switzerland, CH-8001 BAM AG: Theaterstrasse 12, Zurich, Switzerland, CH-8001
(c)	Citizenship: Bellevue: Switzerland BAM AG: Switzerland
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 15117B202
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
	Swiss Financial Market Supervisory Authority (FINMA)
Item 4.	Ownership
(a)	Amount beneficially owned: 1,200,000
(b)	Percent of class: 1.5%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 1,200,000
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 1,200,000
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. This statement is filed jointly by Bellevue and BAM AG. BAM AG is a wholly-owned subsidiary of Bellevue.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Bellevue Group AG

Signature:	/s/ Stefano Montalbano
Name/Title:	Stefano Montalbano/ Chief Financial Officer
Date:	05/11/2026

Signature:	/s/ Christoph Eisenring
Name/Title:	Christoph Eisenring/ Head Legal & Compliance
Date:	05/11/2026

Bellevue Asset Management AG

Signature:	/s/ Christoph Eisenring
Name/Title:	Christoph Eisenring/ Head Legal & Compliance
Date:	05/11/2026

Signature:	/s/ Ivo Betschart
Name/Title:	Ivo Betschart/Chief Finance & Controlling
Date:	05/11/2026